Gabapentinoids Appear Increasingly to be Prescribed, Off-Label, for Cancer Pain

As the opioid crisis unfolded, prescriptions for the narcotic alternative saw a two-fold increase despite unclear evidence of benefit for pain.

1:24 PM

Author | Ian Demsky

Pills spilled out of orange bottle on white surface.

Between 2005 and 2015, as the opioid crisis in America came into focus, prescriptions for gabapentinoid medications — gabapentin and pregabalin — to adults with cancer saw a two-fold increase, a University of Michigan Rogel Cancer Center study has found.

Gabapentin, which affects voltage-gated calcium channels in the brain, was originally approved as an anti-seizure medication and later for treating nerve pain. Today, up to 95% of its use may be "off-label," researchers have found — highlighting a lack of rigorous study of its mechanisms and efficacy for treating pain more broadly, as well as other conditions it's commonly prescribed for, like migraines and fibromyalgia.

The U-M study, which examined federal Medical Expenditure Panel Survey data, presents the first evidence and measurement of a steep upward trend in gabapentinoid prescriptions among adults with cancer, says lead author Alex Fauer, R.N., a doctoral student at the U-M School of Nursing. The findings, which dovetail with broader, national trends, appear in Supportive Care in Cancer.

"Cancer is a disease of aging, so we were surprised to find that adults 18-44 were the largest age group getting these prescriptions," Fauer says. "This may indicate doctors are increasingly prescribing gabapentinoids as an alternative to opioids for treating cancer pain in younger adult patients. It may additionally point to a growing incidence of nerve pain caused by chemotherapy in cancer survivors."

The study found the number of adults with cancer who were prescribed gabapentinoids grew from 3.3% in 2005 to 8.3% in 2015, with the total number of prescriptions growing from 1.2 million to 3.5 million over that decade.

More recent data wasn't available, but likely shows a continuation of the trend, Fauer says. The data also doesn't include inpatient treatment, excluding many of the sickest patients.

Use of gabapentinoids to treat the complex pain syndromes of cancer patients is problematic for a couple of reasons, says senior study author Christopher Friese, Ph.D., R.N., the Elizabeth Tone Hosmer Professor of Nursing and a professor of health management and policy at the U-M School of Public Health.

"The medications' mechanisms of action and efficacy for pain control and other off-label conditions need further study," he says. "Additionally, evidence indicates the healthcare profession may have been underestimating the risks associated with gabapentinoids — including the potential for abuse and physical dependence, and dangers when taken in combination with opioids and other medications."

More investigation of the effectiveness of gabapentinoids for cancer pain is needed to inform clinical practice, Fauer adds, along with deeper understanding of potential risks.

"The whole goal is treating patients' pain while keeping them safe," he says.

The research was supported by funding from the American Cancer Society, Jonas Scholars Program, Hillman Scholars Program in Nursing Innovation, and the National Cancer Institute (P30CA046592).

Paper cited: "Use of gabapentinoid medications among US adults with cancer, 2005–2015,"  Supportive Care in Cancer. DOI: 10.1007/s00520-019-05100-9


More Articles About: Lab Report Drug Abuse and Misuse All Research Topics Health Care Delivery, Policy and Economics Addiction and Substance Abuse Pharmacy
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories sketched out bacteria in a dish yellow and blue colors of U-M
Health Lab
This gross mixture has big benefits for the study of bacteria
Michigan Medicine researchers have found that growing bacteria on agar mixed with organs is an efficient and effective way to study infectious pathogens.
three pharmacists smiling
Health Lab
An innovative pharmacy service for pain management
An innovative service at Michigan Medicine offers pain management support for patients and care teams
green blue map of michigan
Health Lab
How does exposure to ‘forever chemicals’ impact your cancer risk
Pearce, professor of epidemiology at the School of Public Health and co-lead of Rogel’s cancer control and population sciences program, reflects on the project and why bringing this study to Michigan is so critical.
person holding walker with nurse next to them closer up on hands lower body
Health Lab
Long COVID happens in nursing homes, too
Post-acute sequelae of Sars-COV2 (PASC, long COVID) caused a decrease in independence and cognitive ability after coronavirus infection in nursing home residents
expert at stand hearing in suit
Health Lab
Keep telehealth alive and well, experts tell Senate subcommittee
Telehealth coverage by Medicare is scheduled to expire at the end of 2024; experts told Senators what they think should happen to preserve it.
physician talking to patient with lab researcher in background
Health Lab
Older adults left out of clinical research trials
Including older adults in research can be beneficial, explains a Michigan Medicine research, who says more should, and can be, done to have their insights.